Unlocking large-scale cell engineering

Modern therapies and clean meat, while extremely promising, are facing the same bottleneck: large-scale cell culture.
Current bioproduction techniques are indeed limited in both in terms of scalability and efficiency, leading to unmet needs.
Rise of genetherapy
The success of biological drugs in the treatment of major chronic diseases has catapulted acceptance of innovative therapies, including gene therapies.
But large scale manufacturing  of their key component, viral vector, is significantly expensive and face major scalability and quality bottlenecks

from 200k€ up to 2m€ per patient
accounting for up to 80% of
therapy production costs

24 months waitlist
to obtain high value biologics due to
high demand and suboptimal
manufacturing techniques

 Extensive quality control
to be performed (FDA 03/09/2021)
E.g. : 1% produced viral vectors
with a therapeutic effect

Our solution

We create the next-generation of bioreactors specifically designed to handle mammalian cells.
We start with making gene therapy manufacturing more efficient, cost-effective and with a higher quality.
competitive cost

Negligible costly transfection reagents and media consumption
Increased yield thanks to high cell density and purification efficiency
More therapeutic vectors in viral vector doses
Personalized calibrations are made to calculate an optimal hydration range
Users are notified before their hydration levels move above or below that range
Keepinig users In The Blue

How it works

Acoustic waves can be exploited as a low power, low shear and
scalable way of manipulating cells to reduce upstream
production costs and increase production capacity
Coming soon
Join our
contact us
Kolibri is always looking for exceptional and driven talents. Please contact us with a cover letter and resume if you think you may be a good fit.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.